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Objectives:  To examine longitudinal patterns of complexity, continuity, and initiation of treatment 
for youth diagnosed with bipolar disorder. Additionally, we explore bipolar diagnosis stability 
and its relationship to observed treatment patterns. Methods: A cohort of 426 privately 
insured youth (ages 6–18) diagnosed with bipolar disorder was identified from the 2000–2001 
Thomson/Medstat-MarketScan® database. Medication complexity was defined as number of 
different psychotropic medication classes dispensed during a 6-month period following a new 
treatment episode of bipolar disorder. Treatment continuity was examined over a 6-month 
follow-up period, specifically focusing on mood stabilizing medications and antidepressant 
monotherapy. Predictors of complexity and continuity were investigated. Results: Fifty-five 
percent of youth received more than one and 25% received three or more different types of 
psychotropic medication classes during follow-up.  This was contrasted with several youth having 
no prescription fills (21%) and 31% discontinuing mood stabilizing medication. Youth with a 
stable bipolar diagnosis were more likely to have continuity of mood stabilizing prescriptions 
(OR: 4.05), but also greater psychotropic medication complexity. Age, health status/comorbidity, 
and being in a managed care plan were also related to complexity and continuity of psychotropic 
medication class regimens. Conclusions: More evidence is needed on the causal patterns 
leading to increased psychotropic medication complexity and continuity and how diagnosis of 
bipolar disorder may drive treatment patterns.
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which the guidelines suggest may “exacerbate mania.” Therefore, 
it is recommended to use antidepressants in combination with 
a mood stabilizing medication. These issues may be even more 
complicated for younger children who tend to have a less clear 
presentation of bipolar disorder (Ryan et al., 1987; Biederman et al., 
2005; Wozniak, 2005; Goodwin and Jamison, 2007).
In addition to psychiatric comorbidity, lack of evidence regard-
ing effective treatment options for youth with bipolar disorder 
is likely to influence high rates of psychotropic medication use 
found in previous studies (Carlson, 2005; Post and Kowatch, 2006; 
Danielyan et al., 2007). Consequently, clinicians will extrapolate 
from clinical trials, open trial, and case reports that involve adult 
patients (Leibenluft, 2006). It is possible that insufficient evidence 
and uncertainty around efficacy and tolerability of many psycho-
tropic medications used to treat youth with bipolar disorder may 
lead to delays in initiation of treatment, frequent switching pat-
terns, or discontinuity. Additionally, uncertainty may lead to inap-
propriate treatment provision. For instance, one study has shown 
low levels of guideline concordance among youth diagnosed with 
bipolar disorder, including about one-third of youth receiving anti-
depressant monotherapy (Evans-Lacko et al., 2010). Moreover, a 
recent study by Geller et al. (2010), showed that over an 8-year 
follow-up period, less than two-thirds of youth ever received a rec-
ommended antimanic medication. To date, however, there has been 
IntroductIon
The pharmacological management of children and adolescents with 
bipolar disorder is widely recognized as challenging and complex. 
Consequently, youth receive multiple trials of medication, often 
resulting in the concomitant use of several different agents. In a 
survey of parents of youth aged 6–17 years old who had bipolar 
disorder, youth were taking on average 3 (±1.5) medications and 
had completed 6 (±3.7) previous trials of psychotropic medication 
(Bhangoo et al., 2003). Other population based studies of youth 
with bipolar disorder ranging from 0 to 20 years of age have con-
firmed high levels of polypharmacy (Jerrell and Shugart, 2004; 
Moreno et al., 2007; Jerrell, 2008).
Several factors have been implicated as contributing to high 
overall rates of medication use and the frequent medication trials 
among youth with bipolar disorder. For one, youth with bipolar 
disorder often have more psychiatric comorbidities than youth with 
other psychiatric disorders (Geller et al., 1994; Jerrell and Shugart, 
2004; Birmaher et al., 2006; Moreno et al., 2007; Jerrell, 2008). 
The Journal of the American Academy of Child and Adolescent 
Psychiatry (JAACAP) established guidelines that advise treating 
each disorder separately because comorbidity worsens the progno-
sis for youth with bipolar disorder (Kowatch and DelBello, 2005). 
However,  this  is  complicated  because  common  treatments  for 
comorbid disorders may include antidepressants and stimulants Frontiers in Psychiatry  |  Child and Neurodevelopmental Psychiatry    November 2010  | Volume 1  | Article 144  |  2
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Enrollees with 2 years of continuous enrollment did differ from 
those with 1 year of continuous enrollment or less in terms of 
region of residence and plan type, with a higher proportion of 
those with 2 years of continuous enrollment living in the north-
east and fewer living in the west compared to those with 1 year of 
continuous enrollment or less. Also, significantly more persons 
with 2 years of continuous enrollment were in an HMO and fewer 
in a Point of Service Plan (POS) compared to those with 1 year of 
continuous enrollment or less. There were; however, no differences 
among these groups by age or gender. This is not a probabilistically 
representative sample of the nation, but the data include a large 
sample of youth from all regions of the country and all types of 
private insurance plans.
Age was analyzed by the following age groups: 6–11, 12–14, 
15–16, and 17–18 years. It is worth noting the rationale for com-
bining 6- to 11-year-olds in one group because it is a wider range 
than the other age groups. Combining all the elementary school-
aged youth (6–11 years) still resulted in a small sample. To address 
concerns that the 6- to 9-year-olds (N = 33) are developmentally 
quite different from 10- to 11-year-olds (N = 38) and their patterns 
of use might be quite different, several analyses were conducted and 
showed no consistent pattern of differences between these sub-
groups, as described below.
PsychotroPIc medIcatIon measures
 Complexity of psychotropic treatment
Medications were organized into eight major psychotropic classes: 
stimulants, antidepressants, antipsychotics, antiparkinsonian, anxi-
olytics, and sedative/hypnotics, mood stabilizing anticonvulsants, 
and other antimanic agents (i.e., lithium). The complexity of psy-
chotropic treatment was defined as the total number of different 
classes of psychotropic medication prescriptions filled 6 months 
following the initial diagnosis of bipolar disorder.
 Immediate vs. delayed initiation of psychotropic medication
Youth were defined as initiating psychotropic medication immedi-
ately if they filled a prescription for the medication within 1 month 
of their initial diagnosis of bipolar disorder. Youth who filled a pre-
scription for a psychotropic medication more than 1 month follow-
ing initial diagnosis were considered to have delayed initiation.
 Continuity of psychotropic medication treatment
Three mutually exclusive patterns were used to describe psycho-
tropic medication continuity. These groups include: (i) Complete 
discontinuation,  defined  by  the  cessation  of  pharmacotherapy 
with no resumption during the remaining time in the 6 month 
follow-up period; (ii) Non-persistence, defined as discontinuation 
of medication at some point, but resumption of treatment within 
the 6-month follow-up period; and (iii) Continuity, defined as fill-
ing prescriptions for the same medications throughout the entire 
6-month period.
stabIlIty of bIPolar dIagnosIs
Three patterns of care were used to categorize individual’s stability 
of bipolar diagnosis (i) Youth who received a service claim associated 
with a diagnosis of bipolar disorder at least 5 out of the 6 months 
following their initial diagnosis were considered to have a stable 
very little attention given to the sequence or utilization   patterns 
of psychotropic treatment for youth with bipolar disorder as the 
majority of the literature has been based on cross-sectional stud-
ies, and so the field lacks knowledge of how these medications are 
being used over time. To understand these types of medication 
patterns, it is essential to examine longitudinal patterns of use. This 
study addresses this gap by examining longitudinal patterns of the 
complexity, continuity and initiation of psychotropic medication 
and psychotherapy treatment for youth diagnosed with bipolar 
disorder. Additionally, we explore the stability of services associated 
with bipolar disorder and its relationship to the observed treatment 
patterns. Finally, we investigate which factors predict continuity 
of pharmacological treatment. This project was approved by the 
Johns Hopkins University Bloomberg School of Public Health 
Institutional Review Board.
materIals and methods
data source
Data come from the Thomson-Medstat MarketScan (2000–2001) 
database,  a  national  dataset  containing  standardized,  detailed, 
enrollee-specific clinical utilization information across inpatient 
and outpatient services, and prescription drug information from 
approximately 45 employer sponsored health plans. Information on 
filled prescriptions are recorded at the individual level allowing for 
investigation of drug use patterns relating to timing of diagnoses 
(Adamson, 2005). Outpatient pharmacy claim files consist of data 
from all settings including mail order and specialty pharmacies and 
manual and electronically submitted claims. Data from the outpa-
tient pharmacy claim files that were used include enrollee-specific 
de-identified identification number, prescription dispensing date, 
quantity dispensed, and the National Drug Code (NDC). The NDC 
is a unique number assigned by the Food and Drug Administration 
that identifies the manufacturer, the specific medication name and 
strength, and the product package size. Since the medication name 
is not recorded on the pharmacy claims file, the Thomson-Medstat 
MarketScan database was linked to the Multum lexicon database 
using the NDC to extract the drug name (Mumford, 2008).
samPle characterIstIcs
Behavioral health claims of an initial cohort (N = 426) of privately 
insured youth 6–18 years of age who received at least two diag-
noses (i.e., at least two visits associated with a diagnosis of bipolar 
disorder) or an inpatient hospitalization for bipolar disorder were 
examined. This method of case identification has been associated 
with a high positive predictive value (94%) and modest sensitivity 
(80%) (Lurie et al., 1992). The validity of this approach was also 
explored for bipolar disorder in adults and depression (Kashner, 
1998; Unutzer et al., 2000; Blow et al., 2004).
The cohort with a new treatment episode was identified by 
excluding all youth receiving any type of bipolar disorder diagno-
sis during the first 4 months of the 24-month study period. Youth 
who were enrolled in the study period for less than six additional 
months following their initial diagnosis of bipolar disorder were 
also excluded due to insufficient follow-up information. Youth with 
co-occurring seizure disorders who may receive mood stabilizing 
medications for reasons other than treatment of bipolar disorder 
were excluded.www.frontiersin.org  November 2010  | Volume 1  | Article 144  |  3
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results
descrIPtIve characterIstIcs
Youth had a mean age of 14.4 years. About half of youth were male 
(52%). Twelve percent were from a rural area and 88% were from 
an urban/suburban area. More than three-quarters of youth (78%) 
were enrolled in a managed care plan. Antidepressants were the 
most common type of prescription filled (61%). Although psy-
chotropic medication use/prescribing is common for this cohort 
of youth, there was also a substantial proportion who did not have 
any pharmacy claims for a psychotropic medication (14%). Older 
youth (ages 17–18) were less likely to fill a prescription for any type 
of psychotropic medication and younger youth (ages 6–11) were 
more likely to have a prescription filled for a stimulant.
comPlexIty of PsychotroPIc medIcatIon use
Complexity of psychotropic medication use was examined overall 
and by age group. Approximately 21% of youth did not receive any 
psychotropic medication and as many as 25% were prescribed more 
than three different classes of psychotropic medications over the 
6 month follow-up period. The distribution of psychotropic medi-
cation use for 17- to 18-year-olds resembles a left skewed distribu-
tion, with the highest proportion receiving either no medications 
or one agent from a single psychotropic class (59%). Few 17- to 
18-year-olds received four or more different classes of psycho-
tropic medications (9%). Prevalence rates for the 6- to 11-year-old 
group resemble a normal distribution, with several youth receiving 
multiple classes of psychotropic medication (62%) and the mode 
number of medication classes being 2. A higher proportion of youth 
aged 6–9 years old had no psychotropic prescriptions compared 
to youth aged 10–11 years of age (23% vs. 5%). However, a similar 
proportion aged 6–9 years as aged 10–11 years had four or more 
psychotropic prescriptions (10% vs. 13%).
stabIlIty of bIPolar dIagnosIs and comPlexIty of 
PsychotroPIc medIcatIon treatment
Table 1 describes the stability of bipolar diagnosis by demographic, 
clinical, and insurance plan characteristics. Most youth were catego-
rized as having a discontinuous pattern of diagnosis (41%); 38% 
of youth received an intermittent pattern of diagnosis and 21% 
received a continuous pattern of diagnosis for bipolar disorder. 
There was little variation between diagnostic groups in terms of 
demographic characteristics; however, youth with more complex 
medication regimens were more likely to have a continuous pattern 
of bipolar diagnosis. Health severity (as measured by RUB score) 
was also associated with stability of bipolar diagnosis, in that youth 
who have a higher RUB score are more likely to have a continuous 
pattern of bipolar diagnosis.
Figure 1 shows the number of different classes of psychotropic 
medications taken by youth each month for 6 months following 
their initial diagnosis of bipolar disorder as a function of the stabil-
ity of bipolar diagnosis. Of note, stability of bipolar diagnosis was 
not significantly associated with age (p = 0.89). No significant dif-
ferences in number of classes of medication were observed between 
groups at month 1; but, at month 6, youth with a continuous pattern 
of bipolar diagnosis were using more different types of classes of 
psychotropic medication classes. Youth with a continuous pattern 
of diagnosis also tended to increase the number of different classes 
pattern of diagnosis; (ii) Youth who received a service claim asso-
ciated with bipolar disorder in fewer than 5 months, but received 
care for bipolar disorder in the 6th month of the follow-up period 
were considered to have an intermittent pattern; and (iii) Youth 
who stopped receiving claims for bipolar disorder were described 
as having a discontinuous pattern of diagnosis.
health status and comorbIdIty
A youth’s health status and co-existing medical and psychiatric 
morbidities were assessed using the Johns Hopkins Adjusted 
Clinical  Groups  (ACG)  Case  Mix  System,  Version  8.0.  The 
ACG system is well-established, valid, and commonly used to 
adjust for comorbidity (Weiner et al., 1991; Johns Hopkins, 
2001). Adjustments are made for age and gender to individu-
als with similar morbidity and anticipated healthcare resource 
consumption. Individuals are stratified into resource utilization 
bands (RUB) with scores ranging from 0 (none) to 5 (high) 
anticipated use of future healthcare resources. These categories 
have been empirically validated in the US and internationally 
and it has been demonstrated that people with higher RUB’s 
have more severe comorbidity and use more healthcare care 
resources (Weiner et al., 1991; Johns Hopkins, 2001; Reid et al., 
2001; Starfield, 2006).
densIty of PsychIatrIsts
The 2001 Area Resource File (ARF) was used to obtain the availabil-
ity of child psychiatrists in each county (US Department of Health 
and Human Services, 2004). The total number of child psychia-
trists in the youth’s county of residence was divided by the number 
of 6- to 18-year-olds living in the county (also obtained through 
the ARF) to construct the variable density of child psychiatrists for 
youth. ARF data were linked to the claims data using the county of 
residence for each youth.
statIstIcal analysIs
Descriptive statistics were conducted first to assess the overall 2-year 
treated prevalence of the more common psychotropic medications 
as well as the complexity and continuity of psychotropic treatment 
6 months following the initial diagnosis of bipolar disorder. Results 
are also described by age group, sex, geographical region, and ACG 
RUB score. Estimates and 95% confidence intervals were computed 
to characterize the magnitude of the difference between groups.
Logistic regression models with robust standard errors were 
constructed to compare the odds of continuous vs. non-continuous 
use of a mood stabilizer. Although antipsychotics are also indicated 
as a first line treatment for bipolar disorder, they were not included 
in this analysis because very few youth were using an antipsychotic 
without using a mood stabilizer (N = 28). Models include stability 
of bipolar diagnosis in addition to patient age, sex, RUB, density of 
psychiatrists, number of outpatient mental health visits, timing of 
psychotropic medication initiation (immediate vs. delayed), being 
enrolled in a managed care plan (vs. a fee for service plan), and 
use of psychotherapy as these factors are likely to influence the 
probability of being prescribed a mood stabilizer. Model building 
examined for collinearity, interaction, and confounding. All data 
were summarized using SAS version 9.1® (SAS Institute Inc., Cary, 
NC, USA).Frontiers in Psychiatry  |  Child and Neurodevelopmental Psychiatry    November 2010  | Volume 1  | Article 144  |  4
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differences were found for age, use of psychotherapy, and stability 
of bipolar diagnosis. Those with a continuous pattern of diagnosis 
are significantly more likely to initiate and to have continuity of 
a mood stabilizer. Psychotherapy treatment was associated with 
delayed but more continuous use of a mood stabilizer. Regarding 
age, there seems to be a trend that older youth are less likely to 
ever fill a prescription for a mood stabilizer and also less likely 
to establish continuity of mood stabilizing medication. Younger 
youth, also seem to be less likely to have non-persistence of a mood 
stabilizing medication.
of prescriptions filled over the 6-month period, while youth in the 
intermittent or discontinuous group took the same number or 
fewer types of medications over the 6-month follow-up period.
contInuIty and tImIng of InItIatIon of PsychotroPIc 
medIcatIon treatment
Table 2 incorporates timing of initiation and continuity of psy-
chotropic medication to describe five mutually exclusive patterns 
for utilization of mood stabilizing medication by demographic, 
clinical, and insurance plan characteristics. Statistically significant 
Table 1 | Stability of bipolar diagnosis by demographic and clinical characteristics (n = 426).
  Discontinuous pattern, n = 175 (41.1%)  Intermittent pattern, n = 162 (38.0%)   Stable pattern, n = 89 (20.9%)   
  [% (95% confidence interval)]  [% (95% confidence interval)]  [% (95% confidence interval)]
Age
6–11 (N = 65)  40.0 (28.3–52.9)  40.0 (28.3–52.9)  20.0 (11.5–32.1)
12–14 (N = 109)  40.4 (31.2–50.2)  37 .6 (28.7–47 .4)  22.0 (14.9–31.2)
15–16 (N = 129)  41.9 (33.3–50.9)  36.4 (27 .6–46.2)  21.7 (15.1–30.0)
17–18 (N = 123)  41.5 (32.8–50.7)  39.0 (30.0–48.9)  19.5 (13.1–27 .8)
genDeR
M (N = 222)  42.3 (35.8–45.1)  40.5 (34.1–47 .3)  17 .2 (12.6–22.9)
F (N = 204)  39.7 (33.0–46.8)  35.3 (28.8–42.3)  25.0 (19.3–31.6)
RUB
Low (1–3) (N = 211)  44.1 (37 .3–51.1)  37 .4 (31.0–44.4)  *18.5 (13.6–24.5)
Med (4) (N = 168)  35.7 (28.6–43.5)  42.3 (34.8–50.1)  22.0 (16.2–29.2)
High (5) (N = 47)  46.8 (32.4–61.8)  25.5 (14.4–40.6)  27 .6 (16.1–42.9)
MAnAgeD CARe
Fee for service (N = 95)  49.5 (39.1–59.8)  30.5 (21.7–40.9)  20.0 (12.8–29.7)
Managed care (N = 331)  38.7 (33.4–44.2)  40.2 (34.9–45.7)  21.2 (17 .0–26.0)
USe OF PSyChOTheRAPy
Yes (N = 162)  42.0 (34.4–50.0)  35.8 (28.5–43.7)  22.2 (16.2–29.6)
No (N = 264)  40.5 (34.6–46.7)  39.4 (33.5–45.6)  20.1 (15.5–25.5)
*Statistically significant at the p = 0.05 level.
FIgURe 1 | Mean number of classes of psychotropic medication prescriptions filled by stability of bipolar diagnosis by month.www.frontiersin.org  November 2010  | Volume 1  | Article 144  |  5
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Figure 2 shows the continuity and persistence of a mood stabi-
lizing medication for youth by stability of bipolar diagnosis. Youth 
with a continuous pattern of bipolar diagnosis are significantly more 
likely to receive a mood stabilizer in a continuous manner than youth 
with an intermittent or discontinuous pattern of diagnosis and the 
least likely to completely discontinue mood stabilizing medication. 
The group with a discontinuous pattern of bipolar diagnosis is also 
the most likely to completely discontinue mood stabilizing medica-
tion. Figure 3 shows the same relationship between continuity of 
bipolar diagnosis and continuity of pharmacological treatment, but 
for antidepressant monotherapy. Here a different pattern emerges 
with the group having a continuous stable pattern of bipolar diag-
nosis being the most likely to receive antidepressant monotherapy, 
which is not recommended. The group with a continuous stable 
pattern of bipolar diagnosis is still less likely than the discontinu-
ous group to completely discontinue antidepressant monotherapy 
(p = 0.05), and is also less likely than the intermittent group to have 
non-persistent contraindicated antidepressant use (p < 0.05); but, 
there is no statistically significant difference in the continuity of 
antidepressant monotherapy between groups with differing patterns 
of diagnostic stability for bipolar disorder.
multIvarIate analyses
Table 3 shows the results of a logistic regression for the odds of 
receiving a mood stabilizer in a continuous manner by stability of 
bipolar diagnosis when controlling for demographic and service 
utilization characteristics. It appears that youth who are receiving 
a continuous pattern of bipolar diagnosis are more likely to receive 
continuous mood stabilizing prescriptions than youth with a dis-
continuous pattern of bipolar diagnosis. Delaying use of a mood 
stabilizer following initial diagnosis for bipolar disorder; however, 
did not predict later discontinuation/continuity of a mood sta-
bilizer. This is true when controlling for age, sex, health severity/
comorbidity (as measured by RUB score), use of psychotherapy, 
density of psychiatrists, and insurance plan characteristics. Youth 
enrolled in a managed care plan and youth who were more ill (as 
measured by RUB score) were also significantly more likely to have 
continuity of a mood stabilizer or antipsychotic medication.
dIscussIon
Complex medication regimens were common in youth diagnosed 
with bipolar disorder; approximately half of youth (55%) received 
more than one and 25% of youth received three or more different 
Table 2 | Patterns of mood stabilizing prescription fills by demographic, clinical characteristics, and insurance plan characteristics (n = 426).
  % (95% confidence interval)
  never initiated  Delayed initiation  non-persistence  Complete  Continuity 
        discontinuation
Age
6–11 (N = 65)  38.5 (26.9–51.4)  20.0 (11.5–32.1)  *1.5 (0.1–9.4)  20.0 (11.5–32.1)  20.0 (11.5–32.1)
12–14 (N = 109)  36.7 (27 .8–46.5)  18.4 (11.8–27 .2)  *16.5 (10.3–25.1)  12.8 (7 .5–20.9)  15.6 (9.6–24.1)
15–16 (N = 129)  50.5 (41.6–59.3)  16.5 (10.8–24.3)  13.8 (8.5–21.2)  14.7 (9.3–22.2)  22.9 (16.2–31.3)
17–18 (N = 123)  54.5 (45.3–63.4)  13.0 (7 .9–20.6)  12.2 (7 .2, 19.6)  10.6 ( 6.0, 17 .7)  9.8 (5.4, 16.8)
genDeR
M (N = 222)  40.5 (34.1–47 .3)  14.4 (10.2–19.9)  13.1 (9.1–18.3)  15.8 (11.4–21.4)  16.2 (11.8–21.9)
F (N = 204)  47 .6 (40.9–54.3)  17 .2 (12.6–22.9)  9.8 (6.4–14.7)  10.3 (6.8–15.2)  15.2 (10.9–20.8)
RUB
Low (1–3) (N = 21  47 .4 (40.5–54.4)  17 .1 (12.4–23.0)  11.4 (7 .6–16.7)  12.3 (8.3–17 .7)  11.9 (8.0–17 .2)
Med (4) (N = 168)  39.9 (32.5–47 .8)  14.9 (10.1–21.4)  13.1 (8.6–19.4)  14.9 (10.1–21.4)  17 .3 (9.1–24.1)
High(5) (N = 47)  42.6 (28.6–57 .7)  12.8 (5.3–26.5)  6.4 (1.7–18.6)  10.6 (4.0–23.9)  27 .7 (16.1–42.9)
TyPe OF InSURAnCe
Fee for service (N = 95)  50.5 (40.1–60.8)  8.4 (4.0–16.4)  10.5 (5.4–18.9)  10.5 (5.4–18.9)  20.0 (12.8–29.7)
Managed care (N = 331)  42.0 (35.7–47 .5)  17 .8 (13.9–22.4)  11.8 (8.6–15.9)  13.9 (10.5–18.2)  14.5 (11.0–18.9)
FOllOw-UP CARe FOR BIPOlAR DISORDeR
Continuous (N = 89)  *22.5 (13.7–34.4)  19.1 (11.0–30.7)  18.0 (10.2–29.5)  7 .9 (3.1–17 .6)  *32.6 (22.1–45.1)
Intermittent (N = 162)  *46.3 (38.5–54.3)  17 .3 (12.0–24.2)  11.1 (6.9–17 .2)  11.7 (7 .4–17 .9)  *13.6 (8.9–20.1)
Discontinuous (N = 175)  33.5 (26.7–41.1)  7 .3 (4.1–12.5)  5.5 (2.8–10.3)  10.9 (6.9–16.7)  *5.8 (3.0–10.7)
USe OF PSyChOTheRAPy
Yes (N = 162)  *14.6 (9.8–21.0)  *38.0 (30.8–45.8)  9.9 (6.0–15.6)  15.2 (10.3–21.7)  22.2 (16.4–29.3)
No (N = 264)  *47 .8 (41.6–54.1)  *16.5 (12.4–21.8)  12.5 (8.8–17 .3)  11.8 (8.2–16.6)  11.4 (7 .9–16.1)
nUMBeR OF Rx ClASSeS
0 (N = 88)  100.0  0  0  0  0
1 (N = 121)  *74.4 (65.5–81.7)  *4.1 (1.5–9.8)  6.6 (3.1–13.0)  9.9 (5.4–17 .0)  5.0 ( 2.1–11.0)
2 (N = 109)  *26.6 (18.8–36.1)  *30.3 (22.1–40.0)  15.6 (9.6–24.1)  11.0 (6.1–18.8)  16.5 (10.3–25.1)
3+ (N = 108)  *7 .4 (3.5–14.5)  *29.6 (21.4–39.3)  21.3 (14.2–30.4)  19.4 (14.2–30.4)  22.2 (15.0–31.4)
*Statistically significant at the p=0.05 level.Frontiers in Psychiatry  |  Child and Neurodevelopmental Psychiatry    November 2010  | Volume 1  | Article 144  |  6
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classes of psychotropic medications in the 6-month period fol-
lowing initial diagnosis of bipolar disorder. However, only 28% 
of youth continuously used a mood stabilizing medication in the 
6-month follow-up period.
Despite high overall rates of psychotropic medication use, con-
siderable variation in psychotropic medication continuity and 
complexity was apparent in this group of youth diagnosed with 
bipolar disorder. High overall rates of psychotropic medication 
use were contrasted with the finding that several youth had no 
prescriptions filled for psychotropic medication in the 6-month 
period following initial diagnosis of bipolar disorder. Of those 
who initiated a mood stabilizing medication, about 31% discon-
tinued the medication within the 6-month follow-up period. 
Stability of bipolar diagnosis, age, health severity, and insurance 
plan characteristics were all shown to be important factors in 
describing differences in psychotropic medication complexity 
and continuity.
Older age had an interesting relationship with psychotropic 
medication complexity. The 17- to 18-year-old age group had the 
highest proportion with no psychotropic medications filled dur-
ing the 6-month follow-up period and overall in the 2-year study 
period. This may be because this data only included information 
on filled prescriptions and it is possible that medications were 
prescribed but not filled. Therefore, this difference between age 
groups may reflect the fact that 17- to 18-year-olds are less likely 
to fill their prescriptions than youth of other ages. This is often a 
transitional age in which youth gain more independence in terms 
of their healthcare utilization. Although they still have insurance 
coverage, they might lack awareness regarding appropriate treat-
ments and help-seeking or might be resistant to using certain 
psychotropic medications. Nevertheless, this might represent an 
FIgURe 3 | Continuity of contraindicated antidepressant 
prescriptions (without a mood stabilizer or antipsychotic) by stability 
of bipolar diagnosis only including those who ever initiate (n = 142, 
*p < 0.05).
FIgURe 2 | Continuity of mood stabilizing medications by stability of 
bipolar diagnosis – only including those who ever initiate (n = 239, 
*p < 0.05).
Table 3 | logistic regression model for probability of continuity of mood 
stabilizing medication treatment by stability of bipolar disorder 
diagnosis over 6-month follow-up period (n = 211).
  Odds ratio  95% CI
STABIlITy OF BIPOlAR DIAgnOSIS
Discontinuous(ref)   
Intermittent  *2.31  1.17–4.80
Continuous  *4.05  1.83–8.94
Number of mental outpatient  *1.04  1.01–1.06 
mental health visits
Immediate vs. delayed use  1.12  0.59–2.13
Age  0.95  0.85–1.06
Sex
F (ref)   
M  1.05  0.57–1.93
MAnAgeD CARe
Fee for service (ref)   
Managed care  *2.25  1.01–5.04
RUB (ref = low)  0.95  0.62–1.46
Density of psychiatrists  0.87  0.55–1.37 
(per 1,000 youth)
Psychotherapy  0.86  0.46–11.50
*Statistically significant at the p=0.05 level.www.frontiersin.org  November 2010  | Volume 1  | Article 144  |  7
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stabilizer, we can see that almost one-third of youth had already 
initiated psychotherapy, and may have experienced a delay to all 
types of psychotropic treatment.
Youth with a continuous pattern of bipolar diagnosis are more 
likely to establish continuity of a mood stabilizing medication 
emphasizing the connection between diagnosis and treatment and 
the potential for diagnosis to be driving treatment. This relation-
ship, however, may also be due to the phenotypic presentation of 
the youth’s disorder, to the confidence of the provider in making 
the diagnosis and prescribing appropriate treatment, or patient/
familial preferences regarding treatment. Although this study pro-
vides new information on the longitudinal patterns of medication 
continuity and complexity for youth with bipolar disorder, several 
unanswered questions remain surrounding the reasons youth are 
experiencing these different patterns of use. For instance, although 
stability of bipolar diagnosis is positively and significantly associ-
ated with continuity of mood stabilizing medication prescriptions, 
there are also a substantial proportion of youth who have a discon-
tinuous or intermittent pattern of bipolar diagnosis, but are using 
mood stabilizers in a continuous manner. For some youth this 
may be due to a misclassification bias in that the youth may still 
have bipolar disorder, but they were not receiving care or a claim 
associated with bipolar disorder. Nevertheless, it is interesting to 
note that these youth continued to receive pharmacologic treatment 
for bipolar disorder but not a diagnosis for bipolar disorder. This 
finding is supported by previous research which shows a significant 
number of youth being prescribed antipsychotic, mood stabilizing 
and antidepressant medications without presence of an indicating 
diagnosis (Chen et al., 2009).
Moreover, we can not be exactly sure why youth discontinue 
services for bipolar disorder or mood stabilizing medication treat-
ment. Patterns of medication use and continuity of claims for 
bipolar disorder may result from several factors. First, discontinu-
ation of mood stabilizing medication or of treatment for bipolar 
disorder may be due to youth who were initially misdiagnosed 
with bipolar disorder. Discontinuation of mood stabilizing medi-
cation could either be the result of lack of tolerability or ceas-
ing to fill prescriptions of that medication. Non-persistent use of 
medication may be due to non-adherence, but may also be due 
to switching providers. More complex medication regimens may 
be a result of treatments not resolving symptoms and physicians 
adding on additional medications, additional psychiatric comor-
bidities or physician practice style. Additionally some physicians 
may be afraid to remove a medication once it is initiated for fear of 
decompensation. Delayed initiation of a mood stabilizing medica-
tion following diagnosis of bipolar disorder may be the result of 
not seeing a provider immediately who is capable of prescribing 
a medication, reluctance of the provider to immediately initiate 
mood stabilizing medications, or the youth or parent deciding 
not to fill the initial prescription for a mood stabilizer. Finally, 
social, economic and cultural factors can also affect medication 
use and continuity.
There was also a significant positive relationship between con-
traindicated antidepressant use and stability of bipolar diagnosis. 
For youth with a stable pattern of bipolar diagnosis, the likelihood 
of ever initiating antidepressant monotherapy treatment in addi-
tion to maintaining continuous treatment with an antidepressant 
important target group when thinking about further intervention. 
Other differences by age were not statistically significant except 
that younger youth (ages 6–11) were more likely to have a pre-
scription filled for a stimulant. This is likely related to the fact 
that younger youth are also more likely to receive a diagnosis of 
ADHD (Geller et al., 2000).
Surprisingly, age was not statistically significantly associated 
with continuity of mood stabilizing medication in the multivari-
ate analysis. This suggests that once youth were in care age did 
not affect medication utilization patterns. There were however, 
differences in age among ever initiating a mood stabilizer or antip-
sychotic and non-persistent patterns of use. First, youth who were 
less than 15 were significantly more likely to ever fill a prescrip-
tion for a mood stabilizing medication in the 6-month follow-up 
period, than older youth ages 15–18 (p = 0.05). Moreover, older 
youth (12–18) were more likely to have a non-persistent pattern 
of mood stabilizing use compared to younger youth (6–11 years 
of age) (14% vs. 2%). Patterns of discontinuity for mood stabi-
lizing medications were, however, similar among all age groups. 
Therefore, although we might expect older youth to have a more 
traditional phenotype of bipolar disorder and that, subsequently, 
they might be more easily treated and establish continuity of 
medication use, it is possible that lack of adherence is influenc-
ing these patterns.
This study also identified a relationship between stability of 
bipolar diagnosis and continuity and complexity of psychotropic 
medication treatment. Youth who received a continuous pattern 
of diagnosis for bipolar disorder were more likely to receive more 
complex and continuous psychotropic medication treatment regi-
mens than youth for which the diagnosis was discontinued over 
the 6-month follow-up period. Although this may be related to 
the fact that youth with a continuous pattern of diagnosis are a 
sicker group, visit the provider more often, and thus may have 
more  opportunities  to  be  prescribed  additional  psychotropic 
medications in a continuous manner, this relationship remained 
significant after controlling for health severity and number of 
outpatient mental health visits. Youth who received a diagnosis 
of bipolar disorder in a continuous manner were also more likely 
to receive more complex medication regimens when controlling 
for number of outpatient mental healthcare visits. These findings 
suggest that physicians who strongly suspect a diagnosis of bipolar 
disorder in youth are more likely to continue to prescribe or add 
on additional medications over the 6-month follow-up period. 
One explanation for this finding might be that when the diagnosis 
of bipolar disorder is less clear, physicians might be more reluc-
tant to prescribe additional psychotropic medications. Finally, the 
observation that delaying use of a mood stabilizing medication is 
not significantly associated with continuity of a mood stabilizing 
medication suggests that being in treatment for bipolar disorder in 
a continuous manner is a more important factor for maintaining 
continuity of treatment with a mood stabilizer than immediate 
initiation of a mood stabilizer. Of those who delayed initiation 
of a mood stabilizing medication, 37% also delayed initiation of 
a second psychotropic medication. Twenty-seven percent of this 
group initiated psychotherapy without delay and only 7% did not 
take any other psychotropic medications. Therefore, although it 
seems a large proportion of youth are delaying initiation of a mood Frontiers in Psychiatry  |  Child and Neurodevelopmental Psychiatry    November 2010  | Volume 1  | Article 144  |  8
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was not different for youth with a stable pattern of bipolar diagno-
sis vs. an intermittent or discontinuous pattern. Other research has 
also shown that a significant proportion of youth diagnosed with 
bipolar disorder receive antidepressant monotherapy (Moreno 
et al., 2007; Evans-Lacko et al., 2010). This suggests some level 
of uncertainty in terms of appropriate treatment regimen even 
for those with a continuous pattern of bipolar diagnosis. Youth 
with a continuous pattern of bipolar diagnosis were less likely to 
discontinue antidepressant monotherapy treatment compared to 
those with an intermittent or discontinuous pattern of bipolar 
diagnosis. This suggests a relationship between diagnostic uncer-
tainty and patterns of medication use for all types of psychotropic 
treatment – even those that are contraindicated.
lImItatIons
There are some limitations to this research. Despite its strengths, 
claims data have limitations in that the validity of diagnoses cannot 
be verified and the data itself may include coding discrepancies. 
Factors such as misdiagnosis, inaccurate diagnosis or “up-coding” 
for reimbursement may influence diagnostic rates in utilization 
data. We do not mean to propose that all youth in this cohort are 
“true” bipolar cases, we aim to present the treatment and diagnostic 
patterns occurring in practice. Further research is needed to deter-
mine which youth discontinue diagnosis and/or treatment due to: 
misdiagnosis, barriers to care or result from an acute phase of the ill-
ness with subsequent recovery. Moreover, we do not have sufficient 
data to conclude why, in some cases, treatment for bipolar disorder 
continues when the diagnosis is discontinued. A substantial propor-
tion of youth were included in the discontinuous diagnosis group 
and treatment patterns varied among individuals within this group. 
Although we characterize each subgroup to a degree, the data do 
not allow us to examine all of the potential predictors associated 
with each of the diagnostic and treatment patterns. We do not have 
data on some sociodemographic confounders such as education, 
income, race and ethnicity that in addition to undetected personal 
and familial factors may help to explain service utilization patterns. 
This study population excluded those without insurance and was 
not representative of those with insurance provided through some 
mechanism other than employer. These data, however, describe real 
world patterns of medication use by a cohort of children with a 
diagnosis of bipolar disorder.
Regarding  the  selection  of  the  initial  cohort,  youth  who 
did not receive a diagnosis for the first 6 months of the study 
period were considered to be newly diagnosed. However, it is 
possible that some youth received a diagnosis of bipolar dis-
order before this time period and erroneously were considered 
newly diagnosed. Nevertheless, these youth would be expected 
to receive continuous treatment upon reengagement of services. 
Additionally, because the data were based on pharmacy claims, 
we cannot be sure if it was the physician or parent/youth who 
discontinued the medication.
conclusIons
Many youth who receive two or more diagnoses of bipolar disorder 
and/or are hospitalized for that diagnosis do not continue to receive 
treatment for bipolar disorder over the 6-month period following 
diagnosis. Those who do receive a continuous diagnosis of bipolar 
disorder are more likely to receive continuous pharmacological 
treatment for bipolar disorder, but are also more likely to have 
complex regimes with multiple psychotropic agents/medications. 
Nevertheless, among those who continue to receive a diagnosis of 
bipolar disorder and associated care at least monthly, more than half 
do not consistently fill a prescription for a mood stabilizing drug 
and a similarly large proportion receive medications that are cur-
rently contraindicated according to AACAP and other guidelines. 
The difficulties of making this diagnosis accurately in youth and 
of treating early onset bipolar disorder most certainly contribute 
to the fact that most treatment for bipolar disorder in youth is not 
concordant with the treatment guidelines. At this point, we present 
only initial, descriptive trends and further exploration and inves-
tigation of predictive factors of continuity and discontinuity are 
needed. Nonetheless, this study indicates a high level of variability 
in treatment patterns among youth who are continuously insured 
may be useful in guiding policy and new research initiatives.
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